Merck Announces Launch of Pioneering Collaborative Cancer Trials Network
- Details
- Category: Merck
Merck announced the launch of the Merck Oncology Collaborative Trials Network, a pioneering clinical trial network focusing on the development of Merck drug and vaccine candidates being investigated for the treatment and prevention of cancer.
FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women with Osteoporosis
- Details
- Category: Amgen
Amgen Inc. (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved Prolia(TM) (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
Victoza® to be launched in Japan in June
- Details
- Category: Novo Nordisk
Novo Nordisk today announced that it has received approval of the price of Victoza®, a once-daily human GLP-1 analogue for the treatment of type 2 diabetes, from Japan's Central Social Insurance Medical Council (Chuikyo), the advisory committee to the Minister of Health, Labour and Welfare.
AstraZeneca Receives FDA Complete Response Letter for AXANUM New Drug Application
- Details
- Category: AstraZeneca
AstraZeneca has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the new drug application for AXANUM (aspirin/esomeprazole magnesium) tablets.
Sanofi-aventis and Generics Leader Nichi-Iko to Establish New Joint Venture for Generics in Japan
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Nichi-Iko Pharmaceutical Co., Ltd. (Nichi-Iko) (Osaka Stock Exchange and Nagoya Stock Exchange: NIK) have signed an agreement to establish a new joint venture, called sanofi-aventis Nichi-Iko K.K., in order to develop a generic business in Japan.
Novartis announces extension of US regulatory priority review period for FTY720
- Details
- Category: Novartis
Novartis announced that the US Food and Drug Administration (FDA) has extended by three months, to September 2010, its review period for the regulatory approval of FTY720 (fingolimod).
Results of the clinical study CALYPSO Published in The Journal of Clinical Oncology
- Details
- Category: Merck
Results of the clinical study CALYPSO, published online by The Journal of Clinical Oncology, show that patients in this study with platinum-sensitive relapsed ovarian cancer experienced longer progression-free survival than patients taking the current standard of care.
More Pharma News ...
- Genzyme Receives FDA Approval for Lumizyme for Pompe Disease
- European Medicines Agency maintains position on the continued use of Rotarix
- Ranibizumab significantly more effective than standard of care in treating vision loss due to DME
- Abbott to Become No. 1 Pharmaceutical Company in India
- Pfizer Global Manufacturing Announces Plans to Reconfigure its Global Plant Network
- Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
- Sanofi-aventis Announces the Creation of the "Sanofi Espoir" Corporate Foundation